Latest News
FDA Approves Spinraza for SMA
On December 23, the FDA announced that it has approved SpinrazaTM (nusinersen) to treat spinal muscular atrophy, making it the first-ever FDA-approved therapy for SMA. We are thrilled to see […]
Read More ›Cure SMA Participates in a Special FDA Listening Session
Last week, Cure SMA participated in a listening session with FDA Commissioner Robert M. Califf, MD, MACC. The FDA organized the listening session in order to gain a better understanding […]
Read More ›Cure SMA Announces Additional Conference Support for Newly Diagnosed Families
Thanks to the generous funding provided by the Erin Trainor Memorial Fund, Cure SMA is now offering additional support for newly diagnosed families to attend the conference. New for this […]
Read More ›SMA Community Conducts Outreach Visits with Members of Congress
On November 30, members of the SMA community met with 17 different legislative offices— eight from the Senate and nine from the House of Representatives. These Senators and Representatives serve […]
Read More ›Jadon’s Hope Foundation Donates 15 Items to Cure SMA Equipment Pool
Cure SMA recently recieved a donation of nine special tomato feeder seats and six telescopic ramps from Jadon’s Hope Foundation. The feeder seats and ramps were immediately sent out to families […]
Read More ›The Lancet Publishes Data from Phase 2, Open-Label Trial of Spinraza (Nusinersen) in Infants
Today, Lancet published results from the Phase 2, open-label trial of nusinersen (Spinraza) in infants. This trial initiated in 2013, and patients continue to receive the drug. The results show […]
Read More ›